Dieser Humanized Monoklonal Antikörper erkennt spezifisch Trop2 (Sacituzumab Biosimilar) in FACS und in vivo. Er zeigt eine Reaktivität gegenüber Human.
Produktnummer ABIN7795133
Kurzübersicht für Rekombinanter Trop2 (Sacituzumab Biosimilar) Antikörper (ABIN7795133)
Target
Trop2 (Sacituzumab Biosimilar)
Antikörpertyp
Recombinant Antibody
Reaktivität
Human
Wirt
Humanized
Klonalität
Monoklonal
Konjugat
Dieser Trop2 (Sacituzumab Biosimilar) Antikörper ist unkonjugiert
Applikation
Flow Cytometry (FACS), In vivo Studies (in vivo)
Güteklasse
Research Grade
Expressionssystem
Mammalian cells
Verwendungszweck
Sacituzumab Biosimilar, Endotoxin 0.05 EU/mg
Produktmerkmale
What is sacituzumab biosimilar research grade? Sacituzumab Biosimilar uses the same protein sequences as the therapeutic antibody sacituzumab. Sacituzumab govitecan is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate used for the treatment of metastatic triple-negative breast cancer and metastatic urothelial cancer. Triple-negative breast cancer is a type of breast cancer that tests negative for estrogen receptors, progesterone receptors and human epidermal growth factor receptor 2 (HER2) protein. Therefore, triple-negative breast cancer does not respond to hormonal therapy medicines or medicines that target HER2. Sacituzumab govitecan is a conjugate of the humanized anti-Trop-2 monoclonal antibody linked with SN-38, the active metabolite of irinotecan. Each antibody having on average 7.6 Molecules of SN-38 attached. SN-38 is too toxic to administer directly to patients, but linkage to an antibody allows the drug to specifically target cells containing Trop-2.
Aufreinigung
Protein A or G affinity column
Reinheit
>95 % by reducing SDS-PAGE
Endotoxin-Niveau
Less than 0.5 EU/mg of protein as determined by LAL method